Physician profile
William J Powers
NPI 1467792564
$12,566.25
in general payments reported to CMS, 2019-2025
44 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,116 · 2020: $1,620 · 2021: $2,259 · 2022: $1,832 · 2023: $1,556 · 2024: $1,829 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,739.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,450.26 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $2,161.28 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Novo Nordisk INC | $1,601.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Biotech, INC. | $635.59 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $578.71 | 2019-2025 | Gardasil 9, Gardasil, Pifeltro |
| Antares Pharma, INC. | $473.01 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Napo Pharmaceuticals INC | $455.18 | 2019-2024 | Mytesi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.30 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $347.12 | 2019-2025 | Emgality, Reyvow, Mounjaro |
| Abbvie INC. | $243.85 | 2021-2024 | |
| Pfizer INC. | $231.99 | 2024-2025 | |
| Amgen INC. | $205.72 | 2020-2025 | Repatha, Otezla, Repatha |
| Theratechnologies INC. | $160.84 | 2021-2024 | Egrifta, Trogarzo |
| Takeda Pharmaceuticals U.S.A., INC. | $146.16 | 2019-2022 | |
| Genentech USA, INC. | $140.52 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.